Search company, investor...

Founded Year

2007

Stage

Incubator/Accelerator | Alive

Total Raised

$15.39M

About GlycosBio

GlycosBio delivers natural bioactive molecules to the body using engineered lipid absorption technologies. The company uses lipid engineering to develop a library of activated oils (AOs) that unlock therapeutic benefits for patients. It was founded in 2007 and is based in Houston, Texas.

Headquarters Location

2450 Holcombe Boulevard Suite J-510

Houston, Texas, 77021,

United States

346-772-0354

Loading...

Loading...

Expert Collections containing GlycosBio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GlycosBio is included in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

A

Advanced Materials

1,364 items

Companies in the advanced materials space, including polymers, biomaterials, semiconductor materials, and more

GlycosBio Patents

GlycosBio has filed 3 patents.

The 3 most popular patent topics include:

  • dietary supplements
  • fatty acids
  • food additives
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/17/2020

2/21/2023

Vegetable oils, Fatty acids, Nutrition, Dietary supplements, Food additives

Grant

Application Date

1/17/2020

Grant Date

2/21/2023

Title

Related Topics

Vegetable oils, Fatty acids, Nutrition, Dietary supplements, Food additives

Status

Grant

Latest GlycosBio News

Glycos Biotechnologies and Solix BioSystems report positive results from early stage R&D collaboration on algal oils

Aug 20, 2011

Glycos Biotechnologies and Solix BioSystems report positive results from early stage R&D collaboration on algal oils 20 August 2011 Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing high-value biochemicals, and Solix BioSystems, Inc. (Solix), a provider of integrated solutionsand services that enable large scale cultivation of algae, announced their early stageresearch and development collaboration has yielded positive results. These preliminaryexperiments demonstrated the potential for Solix’s algae oil to be converted into a rangeof valuable specialty chemicals through GlycosBio’s suite of proprietary biocatalysts. GlycosBio has a specific interest in synthetic rubber intermediates including bio-derivedisoprene. Solix’s crude algal oil was found to be non-toxic and easily metabolized and upgraded byGlycosBio’s proprietary biocatalysts. Based on the successful production of ethanol fromthe oil, additional studies are planned to convert the oil to other higher value chemicals. The tests were conducted at GlycosBio’s research facilities in Houston and led by Dr.Daniel J. Monticello, the company’s Vice President of Research and Development. Upgrading sustainable, non-food, renewable carbon sources like Solix’s algal oil is acentral element of GlycosBio’s feedstock diversity and technology strategy. It appears the potential range of chemical intermediate products that can beproduced from this algal oil is vast. Converting next generation feedstocks, such as algae-derived fatty acids, is a key dimension of GlycosBio’s long term value creation plan andaligns well with our near term commercial projects in Asia, North America and Europe.More broadly this class of feedstock is important for the entire industry. —Daniel Monticello Glycos Biotechnologies, Inc. is an international biochemical companycommercializing advanced metabolic engineering and microbial strain processes thatconvert multiple low value feedstocks into a range of high value sustainable chemicals. Solix BioSystems, Inc. is a developer of algae production technology designed to generate algal biocrude and other algal products on an industrial scale.

GlycosBio Frequently Asked Questions (FAQ)

  • When was GlycosBio founded?

    GlycosBio was founded in 2007.

  • Where is GlycosBio's headquarters?

    GlycosBio's headquarters is located at 2450 Holcombe Boulevard, Houston.

  • What is GlycosBio's latest funding round?

    GlycosBio's latest funding round is Incubator/Accelerator.

  • How much did GlycosBio raise?

    GlycosBio raised a total of $15.39M.

  • Who are the investors of GlycosBio?

    Investors of GlycosBio include JLabs, Threshold Ventures and Mercury Fund.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.